Battleground: Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin D, and binder confusion

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 168-173

  Kovesdy, Csaba P ^a,b   Mehrotra, Rajnish ^c,d   Kalantar Zadeh, Kamyar ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CALCIUM; CHELATING AGENT; VITAMIN D;

CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; RENAL OSTEODYSTROPHY; REVIEW;

BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHELATING AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 38749153987     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03850907     Document Type: Short Survey

References (49)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
2. Kalpakian MA, Mehrotra. R: Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 20: 139-143, 2007
3. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
4. Bricker NS: On the pathogenesis of the uremic state: An exposition of the "trade-off hypothesis." N Engl J Med 286: 1093-1099, 1972
5. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest 83: 1349-1355, 1989
6. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
7. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876-881, 1988
8. Llach F, Massry SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601-606, 1985
9. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35: 661-669, 1989
10. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G: Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9: 1595-1599, 1994
11. Goodman WG, Coburn JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43: 227-237, 1992
12. Salusky IB, Foley J, Nelson P, Goodman WG: Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324: 527-531, 1991
13. Thurston H, Swales JD: Aluminium and chronic renal failure. BMJ 4: 490, 1971
14. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157-161, 1986
15. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 38: S62-S67, 1992
16. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401, 1996
17. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
18. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
19. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
20. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S: Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 66: 2022-2031, 2004
21. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S: Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int 68: 1258-1266, 2005
22. Qunibi WY, Abouzahr F, Mizani MR, Nolan CR, Arya R, Hunt KJ: Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int 68: 271-277, 2005
23. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44: 1024-1030, 2004
24. Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, Carvalho AB, Neto EM, Canziani ME: The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 21: 2464-2471, 2006
25. Eknoyan G, Levin A, Levin N: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003
26. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
27. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29: 66-71, 1997
28. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427-1432, 1998
29. Kazama JJ, Maruyama H, Narita I, Gejyo F: Maxacalcitol is a possible less phosphatemic vitamin D analog. Ther Apher Dial 9: 352-354, 2005
30. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017-1024, 2002
31. Friedman EA: Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 1: 704-709, 2006
32. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926, 2004
33. Qunibi WY: The CARE study and cardiovascular calcification. Manag Care 15: 1-5, 2006
34. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007
35. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B, for the Alberta Kidney Disease Network: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 22: 2856-2866, 2007
36. Qunibi WY, Moustafa M, Kessler P, Muenz LR, Budoff M: Coronary artery calcification (CAC) in hemodialysis patients (HDP): Preliminary results from the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study [Abstract]. J Am Soc Nephrol 286A-287A, 17: 2006
37. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007
38. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
39. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh L Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
40. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
41. Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42: 96-107, 2003
42. Zhu H, Webb M, Buckley J, Roberts NB: Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders. J Pharm Sci 91: 53-66, 2002
43. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062-1069, 2005
44. Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications. Kidney Int 66: S39-S45, 2004
45. Frazao JM, Chesney RW, Coburn JW: Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 13[Suppl 3]: 68-72, 1998
46. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
47. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
48. Coyne DW: Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2: 3-7, 2007
49. Coyne DW: Practice recommendations based on low, very low, and missing evidence. Clin J Am Soc Nephrol 2: 11-12, 2007